Neena Bitritto-Garg
Stock Analyst at Deutsche Bank
(2.88)
# 1,435
Out of 4,829 analysts
80
Total ratings
45.76%
Success rate
7.38%
Average return
Main Sectors:
Stocks Rated by Neena Bitritto-Garg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACAD ACADIA Pharmaceuticals | Initiates: Hold | $22 | $17.44 | +26.15% | 16 | Feb 11, 2025 | |
| ROIV Roivant Sciences | Maintains: Buy | $14 → $15 | $10.64 | +40.98% | 5 | Apr 3, 2024 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Buy | $36 → $8 | $4.61 | +73.54% | 7 | Mar 11, 2024 | |
| IMVT Immunovant | Initiates: Buy | $50 | $14.02 | +256.63% | 1 | Dec 12, 2023 | |
| NBIX Neurocrine Biosciences | Initiates: Buy | $136 | $115.71 | +17.54% | 7 | Dec 12, 2023 | |
| CMPS COMPASS Pathways | Initiates: Buy | $16 | $3.79 | +322.16% | 4 | Dec 12, 2023 | |
| PRTA Prothena Corporation | Initiates: Buy | $62 | $7.43 | +734.45% | 8 | Dec 12, 2023 | |
| ALEC Alector | Initiates: Buy | $12 | $1.17 | +925.64% | 6 | Dec 12, 2023 | |
| SAGE Sage Therapeutics | Initiates: Hold | $21 | $6.57 | +219.63% | 6 | Dec 12, 2023 | |
| SRPT Sarepta Therapeutics | Initiates: Buy | $109 | $36.27 | +200.52% | 3 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $0.98 | +716.24% | 1 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $1.39 | +619.42% | 4 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $5 | $0.33 | +1,418.83% | 3 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $6 | $3.77 | +59.15% | 5 | Aug 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $2.95 | +611.86% | 1 | Apr 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $23 | $65.08 | -64.66% | 1 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $36 | $19.62 | +83.49% | 2 | Jul 11, 2017 |
ACADIA Pharmaceuticals
Feb 11, 2025
Initiates: Hold
Price Target: $22
Current: $17.44
Upside: +26.15%
Roivant Sciences
Apr 3, 2024
Maintains: Buy
Price Target: $14 → $15
Current: $10.64
Upside: +40.98%
Amylyx Pharmaceuticals
Mar 11, 2024
Maintains: Buy
Price Target: $36 → $8
Current: $4.61
Upside: +73.54%
Immunovant
Dec 12, 2023
Initiates: Buy
Price Target: $50
Current: $14.02
Upside: +256.63%
Neurocrine Biosciences
Dec 12, 2023
Initiates: Buy
Price Target: $136
Current: $115.71
Upside: +17.54%
COMPASS Pathways
Dec 12, 2023
Initiates: Buy
Price Target: $16
Current: $3.79
Upside: +322.16%
Prothena Corporation
Dec 12, 2023
Initiates: Buy
Price Target: $62
Current: $7.43
Upside: +734.45%
Alector
Dec 12, 2023
Initiates: Buy
Price Target: $12
Current: $1.17
Upside: +925.64%
Sage Therapeutics
Dec 12, 2023
Initiates: Hold
Price Target: $21
Current: $6.57
Upside: +219.63%
Sarepta Therapeutics
Dec 12, 2023
Initiates: Buy
Price Target: $109
Current: $36.27
Upside: +200.52%
Dec 12, 2023
Initiates: Buy
Price Target: $8
Current: $0.98
Upside: +716.24%
Jan 9, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $1.39
Upside: +619.42%
Nov 11, 2022
Maintains: Buy
Price Target: $7 → $5
Current: $0.33
Upside: +1,418.83%
Aug 2, 2022
Downgrades: Sell
Price Target: $6
Current: $3.77
Upside: +59.15%
Apr 4, 2022
Initiates: Buy
Price Target: $21
Current: $2.95
Upside: +611.86%
Jul 11, 2017
Initiates: Outperform
Price Target: $23
Current: $65.08
Upside: -64.66%
Jul 11, 2017
Initiates: Outperform
Price Target: $36
Current: $19.62
Upside: +83.49%